Amgen vs Hitachi: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and Hitachi side by side

1. 1910Hitachi

   Founding and First Induction Motor

   Namihei Odaira establishes the machinery repair shop that becomes Hitachi, and develops Japan's first 5-horsepower induction motor, establishing the foundation for the company's dominance in electrical engineering.

2. 1932Hitachi

   Expansion into Railway Technology

   Hitachi begins manufacturing electric locomotives and rail signaling systems, establishing a deep, institutionalized relationship with the Japanese national railway network that would evolve into the modern Hitachi Rail division.

3. 1959Hitachi

   Entry into Computing and Electronics

   Hitachi develops its first electronic computer, the HITAC, marking the company's strategic entry into the information technology sector and laying the groundwork for its future digital systems business.

4. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

5. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

6. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

7. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

8. 1989Amgen

   FDA approves Epogen

   The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

9. 1991Amgen

   Neupogen approved, giving Amgen a second franchise

   The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

10. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

11. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

12. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

13. 2009Hitachi

    Record Annual Loss

    Hitachi reported a net loss of about 787 billion yen for the year to March 2009, then the largest by a Japanese manufacturer.

14. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

15. 2016Hitachi

    Toshiaki Higashihara becomes CEO

    Toshiaki Higashihara became CEO of Hitachi in 2016. Shifted Hitachi from a sprawling conglomerate toward infrastructure and digital businesses.

16. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

17. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

18. 2020Hitachi

    Acquisition of ABB's Power Grids Business

    Hitachi executes the $11 billion acquisition of ABB's Power Grids business, renaming it Hitachi Energy and instantly establishing the company as the global leader in HVDC transmission and grid infrastructure.

19. 2021Hitachi

    Acquisition of GlobalLogic

    The company acquires the global digital engineering firm GlobalLogic for $9.6 billion, instantly establishing Hitachi as a top-tier provider of advanced software and product design services for the automotive and telecommunications sectors.

20. 2022Hitachi

    Hitachi Construction Machinery Stake Sale

    Hitachi sold a controlling stake in Hitachi Construction Machinery to Itochu and Japan Industrial Partners, part of its exit from cyclical listed subsidiaries.

21. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

22. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

23. 2024Hitachi

    Acquired Thales Ground Transportation Systems

    Hitachi acquired Thales Ground Transportation Systems. Hitachi Rail completed its ~$1.88 billion (EUR 1.66 billion) acquisition of Thales's Ground Transportation Systems business, its rail signalling division, expanding Hitachi Rail to 51 countries and shiftin…

24. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

25. 2025Hitachi

    Toshiaki Tokunaga Becomes CEO

    Toshiaki Tokunaga became President and CEO on April 1, 2025, succeeding Keiji Kojima, who became Executive Chairman.

26. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

27. 2026Hitachi

    Record Results and Home Appliance Sale

    Hitachi reported record FY2025 profit in April 2026 and agreed to sell 80.1% of its home appliance business to Nojima for about $737 million (¥110 billion).

Acquisitions

Questions about Amgen vs Hitachi